A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis
Information source: Greiner, Jack V., OD DO PhD
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Conjunctivitis, Allergic
Intervention: Olopatadine (Drug); Fluticasone (Drug); Saline (Drug); Artificial tears (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Greiner, Jack V., OD DO PhD Official(s) and/or principal investigator(s): Jack V Greiner, OD, DO, PhD, Principal Investigator, Affiliation: ORA, Inc.
Summary
To compare the clinical efficacy of olopatadine and fluticasone in a 3-week single center,
double-masked, randomized, placebo controlled parallel treatment conjunctival allergen
challenge (CAC) study in patients with allergic conjunctivitis
Clinical Details
Official title: A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Ocular itching
Secondary outcome: Ocular redness
Detailed description:
Study will evaluate the efficacy of nasal anti-allergic therapy compared to ocular
anti-allergic therapy in the prevention of ocular allergic symptoms.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- At least 18 years of age & either sex, any race
- Willing and able to follow all instructions and attend all study visits
- Positive history of ocular allergies
- Reproducible positive ocular allergic reaction induced by conjunctival allergen
challenge
Exclusion Criteria:
- Have planned surgery during trial period
- Female currently pregnant, planning a pregnancy, or lactating
- Use of disallowed medications
Locations and Contacts
Ophthalmic Research Associates, Inc, North Andover, Massachusetts 01845, United States
Additional Information
Starting date: February 2008
Last updated: April 2, 2008
|